Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Climb Bio (Nasdaq: CLYM) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The company's executive team will deliver a presentation on February 12, 2025, at 9:20 a.m. ET.
The virtual conference will feature both a formal presentation and one-on-one investor meetings. The event provides an opportunity for investors and stakeholders to gain insights into Climb Bio's developments and strategic initiatives.
Positive
- None.
Negative
- None.
News Market Reaction – CLYM
In the trading session that priced this news, CLYM declined 6.03%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually February 11-12, 2025.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Format: Presentation and one-on-one investor meetings
Date: February 12, 2025
Time: 9:20 a.m. ET
Webcast: Click here
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.
Investors
Chris Brinzey
ICR Healthcare
chris.brinzey@icrhealthcare.com
339-970-2843
Media
Jon Yu
ICR Healthcare
jon.yu@icrhealthcare.com
475-395-5375
